On SAGE Insight: Marking Blood Cancer Awareness Month: Toward a Biology-Driven Treatment Strategy for Peripheral T-cell Lymphoma

From Clinical Medicine Insights: Blood Disorders

To mark Blood Cancer Awareness Month 2018, SAGE is delighted to offer free access to this great article on SAGE Insight.

T-cell and natural killer–cell lymphomas are a relatively rare and heterogeneous group of diseases that are difficult to treat and usually have poor outcomes. They account for less than 20% of non-Hodgkin lymphoma. There is a pressing need to find better treatments. An increased understanding of the biology of these diseases has led to specific therapies such as antiviral agents and mogamulizumab. This article highlights the unique biological characteristics of some of the different subtypes and discuss how these may be targeted to provide more individualized and effective treatment approaches. Emerging evidence suggests that a more informative way of thinking about these subtypes is to reclassify them as reflected by the revised WHO classification system. Targeting driver mutations in these different groups offers hope of more personalized and effective treatments. The challenge to the international community is to develop biologically driven trials in subtypes of patients with T-cell NHL using a sufficient number of participants to show statistically meaningful results.

Abstract

T-cell and natural killer–cell lymphomas are a relatively rare and heterogeneous group of diseases that are difficult to treat and usually have poor outcomes. To date, therapeutic interventions are of limited efficacy and there is a pressing need to find better treatments. In recent years, advances in molecular biology have helped to elucidate the underlying genetic complexity of this group of diseases and to identify mutations and signaling pathways involved in lymphomagenesis. In this review, we highlight the unique biological characteristics of some of the different subtypes and discuss how these may be targeted to provide more individualized and effective treatment approaches.

Read the article in full here

Article details
Toward a Biology-Driven Treatment Strategy for Peripheral T-cell Lymphoma
CAT Hildyard, S Shiekh,  JAB Browning, GP Collins
First Published April 24, 2017
DOI: 10.1177/1179545X17705863
From Clinical Medicine Insights: Blood Disorders

 

 

     
This entry was posted in Medicine, SAGE Insight and tagged , , , . Bookmark the permalink.

Leave a Reply